Area of research
Hepatology · Surgery
Research interest
Research interests include Hepatocellular Carcinoma Treatment and Prognosis, Cholangiocarcinoma and Gallbladder Cancer Studies, Cancer Immunotherapy and Biomarkers, and Cancer Mechanisms and Therapy.
Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial
Decoding tumor heterogeneity with imaging biomarkers predicts response to TACE plus immunotherapy and targeted therapy in HCC (CHANCE2204)
Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study
Tumor burden with AFP improves survival prediction for TACE-treated patients with HCC: An international observational study☆
Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)
Arterial chemotherapy for hepatocellular carcinoma in China: consensus recommendations
Irradiation stent with 125I plus TACE versus sorafenib plus TACE for hepatocellular carcinoma with major portal vein tumor thrombosis: a multicenter randomized trial
Effect of different <scp>PD</scp>‐1 inhibitor combination therapies for unresectable intrahepatic cholangiocarcinoma
Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition)
Efficacy and safety of camrelizumab plus transarterial chemoembolization in intermediate to advanced hepatocellular carcinoma patients: A prospective, multi-center, real-world study
Optimal time point of response assessment for predicting survival is associated with tumor burden in hepatocellular carcinoma receiving repeated transarterial chemoembolization
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study
Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial
Exploratory Analysis to Identify Candidates Benefitting from Combination Therapy of Transarterial Chemoembolization and Sorafenib for First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Observational Study
Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study
Comparison on hypoglycemic and antioxidant activities of the fresh and dried Portulaca oleracea L. in insulin-resistant HepG2 cells and streptozotocin-induced C57BL/6J diabetic mice
Multi-target lentivirus specific to hepatocellular carcinoma: In vitro and in vivo studies